darzalex 400mg/20 ml inj 400 mg/20ml
مستودع أدوية أداتكو - adatco drug store - daratumumab 400 mg/20ml - 400 mg/20ml
imfinzi 500 mg/10 ml
مستودع ادوية شاوي و رشيدات و مسنات - shawi & rushedat drug store - durvalumab 500 mg/10 ml - 500 mg/10 ml
tecentriq 1200mg/20ml 1200 mg/20ml
مستودع ادوية شاوي و رشيدات و مسنات - shawi & rushedat drug store - atezolizumab 1200 mg/20ml - 1200 mg/20ml
imfinzi 120 mg / 2.4 ml solution for infusion
astrazeneca uk limited, united kingdom - durvalumab - solution for infusion - 50 mg/ml
imfinzi 500 mg / 10 ml solution for infusion
astrazeneca uk limited, united kingdom - durvalumab - solution for infusion - 50 mg/ml
darzalex 1800 mg per 15 ml solution for injection
janssen pharmaceutica n.v, belgium - daratumumab - solution for injection - 1800 mg
padcev® powder for concentrate for solution for infusion 20mgvial
astellas pharma singapore pte. ltd. - enfortumab vedotin - injection, powder, lyophilized, for solution - enfortumab vedotin 20.0 mg/vial
padcev® powder for concentrate for solution for infusion 30mgvial
astellas pharma singapore pte. ltd. - enfortumab vedotin - injection, powder, lyophilized, for solution - enfortumab vedotin 30.0 mg/vial
minjuvi 200mg
medison pharma ltd - tafasitamab - powder for concentrate for solution for infusion - tafasitamab 200 mg - tafasitamab - minjuvi is indicated in combination with lenalidomide followed by minjuvi monotherapy for the treatment of adult patients with relapsed or refractory diffuse large b cell lymphoma (dlbcl) who are not eligible for autologous stem cell transplant (asct).
sarclisa concentrate for solution for infusion 20mgml
sanofi-aventis singapore pte. ltd. - isatuximab - infusion, solution concentrate - isatuximab 20mg/ml